Cristina Ciudad Blanco, Irene Sánchez Gutiérrez, Raquel Rivera Díaz, Pablo Fernández González, Alba Sánchez Orta, Adrián Imbernón Moya, Carmen Romero Ferreiro, Fernando Alfageme Roldán, en representación del Grupo de Estudio de Hidradenitis Supurativa de Madrid (MADHS)
Secukinumab was associated with clinical improvement and an acceptable safety profile in patients with moderate-to-severe HS treated in routine clinical practice.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic skin disease in which interleukin17 (IL-17) plays a significant role. Secukinumab, a monoclonal antibody that selectively blocks the action of IL-17A, is one of the approved therapies for its treatment.
OBJECTIVES: To evaluate the effectiveness and safety of secukinumab for the treatment of moderate to severe HS.
METHODS: A multicenter observational study was conducted, including patients with HS treated with secukinumab. The primary endpoint was effectiveness in terms of the change observed in the International Hidradenitis Suppurativa Severity Score (IHS4) and the percentage of patients who achieved Hidradenitis Suppurativa Clinical Response (HiSCR) and IHS4-55 scores by 48weeks of treatment. Quality of life was also assessed using the Dermatology Life Quality Index (DLQI), and pain was assessed using the visual analog scale (VAS).
RESULTS: 157 patients were included, 62% of whom had severe Hurley stageIII disease. A significant reduction in IHS4, DLQI, and VAS scores was observed from baseline to 48weeks after secukinumab treatment. 75% of patients achieved HiSCR at week48. At 48weeks, 72%, 68%, and 58% of patients, respectively, achieved an IHS4-55, MCID on the DLQI, and a VAS score <3. Treatment was discontinued at 28.6%. Adverse effects were reported in 17% of patients.
CONCLUSIONS: Secukinumab was associated with clinical improvement and an acceptable safety profile in patients with moderate-to-severe HS treated in routine clinical practice.